Another Failure For Biohaven’s Troriluzole
Alzheimer’s Study Misses
Executive Summary
Biohaven’s investigational glutamate modulator troriluzole did not improve symptoms in patients with mild-to-moderate disease, adding to the list of failures in Alzheimer’s disease, as well as for the product itself.
You may also be interested in...
Biohaven’s Life Without CGRP Inhibitors Gets Off To A Rocky Start
With the sale of its migraine portfolio to Pfizer pending, Biohaven said troriluzole – a lead asset in the pipeline soon to be spun out in a new company – failed in a Phase III trial.
Biohaven Gets Pfizer’s Help To Make Nurtec An Ex-US Success Story Too
As the only oral CGRP migraine therapy approved for both prevention and acute therapy, Nurtec has taken significant US market share. Biohaven will call on Pfizer’s expertise and contacts to repeat that success abroad.
Biohaven Faces Another Pipeline Upset, But Focus Remains On Migraine Portfolio
The company, which has reported no R&D successes outside of its CGRP inhibitor platform, said verdiperstat did not differentiate from placebo on any endpoints in multiple system atrophy.